Protocol Ledger

NCT06632977 · Phase II · RECRUITING

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Interventional Phase II clinical trial protocol NCT06632977 sponsored by Alliance for Clinical Trials in Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-06 Enrollment: 474 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06632977
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)474 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06632977
Protocol FieldVerified Registry Value
NCT IdentifierNCT06632977
Consolidated Lead SponsorAlliance for Clinical Trials in Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment474 participants (ESTIMATED)
Registered Start Date2025-02-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI